John Gillard, CEO of Trinity Biotech, emphasized that their patented technology is set to disrupt the CGM market, which is expected to surpass $20 billion by 2029. He highlighted the ergonomic ...

Commenting, Sam Chawla of Perceptive stated that “We are very excited to partner with the new Trinity Biotech management team in developing a disruptive technology for CGM and the broader ...

Trinity Biotech undertakes no obligation to publicly ... reusable and affordable continuous glucose monitor or CGM. We believe that Trinity biosensor technology will initially allow us to launch ...

Trinity Biotech's next-generation CGM system includes reusable and rechargeable components, aiming to make the technology more affordable and environmentally friendly. This development could ...

Trinity Biotech plc has announced encouraging results from its recent pre-pivotal clinical trial of its next-generation continuous glucose monitoring (CGM) system, targeting diabetes management.

As previously announced, Trinity Biotech has entered into a non-binding Letter of Intent with Bayer for the launch of a CGM device in China and India. As part of this, Trinity Biotech is launching ...

Trinity Biotech (TRIB) announced new findings from ... performance for its next-generation continuous glucose monitoring, CGM, system. The latest analysis confirms that first-day accuracy ...